| |
|
Roland Buelow, Ph.D., Chief Executive Officer, Founder and Director
Dr. Buelow has worked in biotechnology for over twenty years and has extensive pharmaceutical experience. Dr. Buelow was a founder of THP Inc.,
a biotechnology company which engineered rabbits to produce human antibodies and was acquired by Roche in March 2007. Between 1993 and 2003,
Dr. Buelow was senior vice president of Research and Development at SangStat Medical Corporation, where he developed RDP58, an anti-inflammatory
compound that demonstrated efficacy in a placebo-controlled, blinded Phase II study in ulcerative colitis patients. Dr. Buelow has published more
than 100 manuscripts and is an inventor on more than 25 patents
Richard Murdock, Chairman
Mr. Murdock has over 30 years of experience in executive management, fund raising, marketing and business development in the biotech therapeutics
and medical device industries. He has served as CEO for SangStat Medical Corporation (acquired by Genzyme Corporation), Kyphon Inc., and Cellpro,
Inc. At Baxter International Inc., Mr. Murdock ran the Fenwal Automation Business Unit and later The Fenwal Europe Business Unit. Mr. Murdock has
helped several start-up companies, including Hemascience Laboratories Inc., Cytogen Corporation, and Haemonetics Corporation.
Ron Eastman, Managing Director, Essex Woodlands Health Ventures
Mr. Eastman became a director of OMT in January 2008 with the investment of Essex Woodlands Health Ventures. Mr. Eastman has over 30 years of
experience building healthcare businesses. He spent 15 years at American Cyanamid Company (now Wyeth) managing various pharmaceutical products,
divisions and subsidiaries in the U.S. and overseas. After Cyanamid, Mr. Eastman helped build three private healthcare companies — Geron
Corporation, HCORP, Inc., and Rinat Neuroscience Corporation. Under his leadership, Geron became a cutting edge biotech company that grew from
a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. Before it was sold, HCORP quickly
established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services. At Rinat, a
biotech company spun out of Genentech in 2001, Mr. Eastman led the effort to recruit an experienced management team and move Rinat's first
product into clinical trials. Pfizer Inc. acquired Rinat in 2006.
Thomas D. Kiley, Esq., Director
Mr. Kiley became a director of OMT in December 2008. He is also an attorney, consultant and director of Geron Corporation, Transcept Pharmaceuticals,
Inc., and four other private companies. In his career, Mr. Kiley has served as a director of more than two dozen companies, principally in the life
sciences, including GenPharm International, Inc. (acquired by Medarex, Inc.) which developed the huMab mouse. From 1980-1988, he was an officer of
Genentech, Inc., serving as general counsel, vice president for legal affairs, and vice president for corporate development. From 1969-1980, Mr.
Kiley practiced intellectual property law at Lyon and Lyon, where he became a partner in 1975. He received his B.S.Ch.E. from The Pennsylvania
State University in 1965 and his J.D. degree from George Washington University School of Law in 1969.
Scientific Advisory Board
Ignacio Anegon, M.D.
Dr. Ignacio Anegon is an immunologist with 25 years of experience in immuno-regulation and functional genomics. As a director of INSERM
(a French academic biomedical research organization), he manages 120 people researching organ transplantation. His group is particularly
interested in immune tolerance induction in organ transplantation by the use of tolerogenic dendritic cells and T CD8 regulatory cells.
Dr. Anegon is also a director of the Rat Transgenesis Facility of OUEST - Genopole, a cluster of French academic laboratories that work in
the field of genomics. Dr. Anegon has published over 140 scientific manuscripts and is editor of the book Rat Genomics (Relié).
Marianne Brüggemann, Ph.D.
Dr. Brüggemann is head of the Antibody Development Laboratory at the Babraham Institute in Cambridge, UK. Her work on the expression of
human antibody repertoires in transgenic mice led to a 1988 patent, held jointly by the Research Councils AFRC (now BBSRC) and Medical Research
Council. She has published numerous papers on: antibody expression, transgenesis, translocus construction on large yeast artificial chromosomes,
antibody knock-out technology using embryonic stem cells, and expression of heavy-chain-only antibodies. Dr. Brüggemann received her Ph.D. from
Professor Rajewsky's Laboratory, Institute for Genetics, University of Cologne, Germany. She is the inventor on twelve patents, half of which
have been granted.
C. Geoffrey Davis, Ph.D.
Dr. Davis is President and CEO of Angelica Therapeutics, Inc., a private company developing antibody-based and antibody-like therapeutics for
the management of Mantle Cell Lymphoma. Prior to Angelica Therapeutics, Dr. Davis was a founder and the chief scientific officer of Abgenix, Inc.,
where he led the development of the XenoMouse® technology, was involved in the research and development of VectabixTM, a fully human monoclonal
antibody recently approved for colorectal cancer, and guided the discovery of eleven other antibodies currently in clinical trials. Amgen Inc.
acquired Abgenix in 2006. Earlier in his career, Dr. Davis was a faculty member at University of California, San Francisco, an investigator with
the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corporation and Cell Genesys, Inc. Dr. Davis received his Ph.D.
in immunology from UCSF and completed his postdoctoral work at Southwestern University. He is the author of 37 publications and inventor on seven
issued patents.
Michael S. Neuberger, Ph.D., FRS
Dr. Neuberger is Joint Head of the Division of Protein and Nucleic Acid Chemistry at the Medical Research Council Laboratory of Molecular Biology
in Cambridge, UK and Honorary Professor of Molecular Immunology at the University of Cambridge. In his 25 years of work on antibodies, he has made
key discoveries on the molecular mechanisms of antibody gene expression and diversification as well as important contributions to the major
technologies underpinning antibody engineering. Professor Neuberger has published more than 150 manuscripts and is the inventor of several
patents and applications in the field of antibody engineering.
Andrew M. Scharenberg, M.D.
Dr. Scharenberg is a professor of Pediatrics and Immunology at the University of Washington, a principal investigator at Seattle Children's
Research Institute, and co-director of the Northwest Genome Engineering Consortium. Dr. Scharenberg is internationally recognized for his work
on B-cell antigen receptor signaling and B-lymphocyte biology. His recent research has focused on the engineering and application of endonucleases
for targeted gene modification in model organisms and hematopoietic stem cells. Dr. Scharenberg completed a B.S. in Biochemistry from Indiana
University, an M.D with distinction and residency training at the University of North Carolina, and post-doctoral work at Harvard Medical
School. He has received numerous honors and awards and authored over 65 publications. Dr. Scharenberg holds three published or pending patents.
|
|
|
